NASDAQ: ACAD · Biotechnology
Over the past week, Acadia Pharmaceuticals (ACAD) racked up 8 mentions across Reddit, X and news, and the read is an Adanos Hold. That is too little tracked discussion to read a direction from, so the signal stays neutral. Wall Street is more constructive, with 16 of 21 analysts rating ACAD a buy.
Tracked discussion on ACAD is too thin this week to read a direction from, which is why it reads as a Hold.
Wall Street’s 76% buy share sits next to a crowd that ranges from X at 0% to News at 25%. No other tracker puts the two side by side.
21 analysts have weighed in: a Strong Buy consensus: 16 buy calls against 1 sell, with an average 12-month price target of $33.50.
The Adanos signal blends each source’s bullish ratio, source breadth, buzz intensity and 3-day momentum. This week ACAD carries too few tracked mentions to weigh any of them, so the read is Hold rather than a clear buy or sell.
Analysts sit 68 points above the crowd average of 8%, the professionals are more constructive than retail. The split is inside the crowd: News reads 25% bullish while X sits at 0%, a 25-point spread that single-source trackers miss.
Over the 30-day window, Acadia Pharmaceuticals (ACAD) buzz held subdued around 14.0 while the price drifted up 10.3% across the period. The chart tracks how social and news attention moved against end-of-day price. Average daily trading volume across the displayed trading days is 1.7M shares. Updated Aug 15, 2026. Over the last 7 trading days, ACAD lost 0.7%. Buzz activity in the recent week averaged 18.8 and was relatively stable, swinging between 14.0 and 21.9. Recent volume is in line with the 30-day average, reflecting steady institutional and retail participation. Daily crowd sentiment leaned bullish on 10 of the 13 days with directional mentions, shown as the green, grey and red breakdown bars below the chart.
Signal metrics use the latest 7 days; contributor and breadth context uses the 30-day chart window.
No Polymarket data for this stock this week.
Query sentiment for ACAD and 2000+ stocks from your terminal. Filter by source, timeframe and signal strength.
View CLIEmbed live ACAD sentiment on your own site with drop-in web components.
View WidgetsThis week’s sentiment from Adanos, with fundamentals and analyst consensus. A quick-reference snapshot for Aug 15, 2026.
| Adanos signal | Hold |
|---|---|
| Analyst consensus | Strong Buy (16 / 4 / 1) |
| Crowd bullish (7d) | 8% |
| Avg price target | $33.50 |
| Most bullish source | News, 25% |
| Most bearish source | X, 0% |
| Sentiment spread | 25 pts |
| Mentions (7d) | 8 |
| Market cap | $4.87B |
| P/E · Forward P/E | 12.7 · 71.4 |
| EPS · Beta | $2.23 · 0.8 |
| Revenue (TTM) | $1.14B · 33% margin |
| Industry | Biotechnology |
Adanos will not call Acadia Pharmaceuticals (ACAD) either way right now. The last 7 days carry 8 tracked mentions across 3 sources, under the 10-mention floor, so the signal sits at a neutral hold with 40/100 conviction. This is a sentiment-based reading, not financial advice.
Reddit discussion around Acadia Pharmaceuticals (ACAD) is fairly quiet with 0 mentions over the last 7 days; the 30-day context spans 2 tracked subreddits. The 7-day tone is 0% bullish; 3-day activity momentum is stable, suggesting steady attention.
There is not enough tracked discussion on Acadia Pharmaceuticals (ACAD) to call it either way. The last 7 days carry 8 tracked mentions across 3 sources, under the 10-mention floor Adanos needs before it reads a direction. On the professional side, 16 of 21 analysts rate ACAD a buy.
Of the 21 analysts covering Acadia Pharmaceuticals (ACAD), 16 rate it a buy, 4 a hold and 1 a sell, for a strong buy consensus. The average price target is $33.50. That puts the street ahead of the crowd, which averages 8% bullish.
Acadia Pharmaceuticals (ACAD) does not carry enough tracked discussion this week to have a readable sentiment. 8 mentions across 3 sources is under the 10-mention floor, so the signal stays neutral at 40/100 conviction.
Not for a reason found in the sentiment itself. Acadia Pharmaceuticals (ACAD) drew 8 tracked mentions in the last 7 days, too small a sample to read a direction from, so Adanos holds the signal neutral instead of calling a buy or sell off it.
News is the dominant discussion channel with 8 mentions (100% of total volume). There is too little of it to read a sentiment direction from.
The Adanos signal blends bullish ratio, buzz score, source breadth and 3-day activity momentum into a single buy/sell reading. ACAD's hold signal at 40/100 conviction reflects a sample too thin to read a direction from. It is a research shortcut, not financial advice.
The ACAD sentiment page is regenerated from the latest 7-day tracking window at each build. Data reflects the most recent Reddit posts, tweets and news articles available in the current publishing cycle.
Peers are ranked first by matching the Hold signal, then by the closest bullish ratio. Discussion activity breaks any remaining ties.
Every data point on this page comes from the Adanos sentiment APIs. Get a free API key and start querying Reddit, X, News and Polymarket sentiment programmatically.
Get Free API Key